Day: August 30, 2020

一个预先安排的独立安全监测委员会（SMC）建议使用opaganib治疗新冠肺炎的美国2期研究按原方案进行；该项研究的患者招募已完成超过50%，预计招募工作将在未来数周完成—与美国2期研究同时进行的opaganib治疗新冠肺炎全球2/3期研究在意大利获得批准；这项研究已经在英国、俄罗斯和墨西哥获得批准，并正在其他一些国家接受审核—opaganib全球2/3期研究已完成首批患者招募，总共计划在40处临床研究中心招募270名重症新冠肺炎住院患者—最早可能于2020年第四季度提交全球紧急用药申请

預先排定的獨立安全監控委員會（SMC）已提出建議，使用 opaganib 進行的美國第 2 期 COVID-19 研究繼續進行並保持不變；目前研究的納入率超過 50％，並且計劃在未來幾週內完成納入—使用 opaganib 的全球第 2/3 期 COVID-19 研究與美國第 2 期研究平行進行，並在意大利順利獲批；而該研究也已在英國、俄羅斯和墨西哥獲得批准，且正在其他國家/地區進行審查—使用 opaganib 進行的全球第 2/3 期研究計劃已納入首批患者，計劃在 40 個臨床中心納入最多 270 名嚴重 COVID-19 肺炎住院患者—計劃最早在 2020 年第四季提交全球緊急用途申請

Not for distribution to United States newswire services or for dissemination in the United States. All figures in Canadian dollars unless otherwise specified.

SACRAMENTO, Calif., Aug. 30, 2020 (GLOBE NEWSWIRE) — Vibe Bioscience Ltd. (CSE:VIBE, OTC:VBSCF, GERMANY:A061) (the “Company” or “Vibe”), a California based cannabis retailer and cultivator, is pleased to announce it has entered into a definitive agreement to acquire Cathedral Asset Holding Corporation (“CAHC” or “Cathedral”) and its distribution and manufacturing assets in Santa Rosa, California. CAHC is a wholly owned subsidiary of Ventura Cannabis and Wellness Corp. (CSE: VCAN) (“Ventura”)“The acquisition of Cathedral makes Vibe a true, vertically integrated cannabis cultivator, distributor, manufacturer and retailer in California, focused on the most dynamic cannabis market in the United States. Vibe is singularly focused on developing cannabis assets that are cash flow positive, and we anticipate the acquisition will be highly...

RIYADH, Saudi Arabia and STOCKHOLM, Sweden, Aug. 30, 2020 (GLOBE NEWSWIRE) — The Saudi Stock Exchange (Tadawul) announced today it has officially launched its first Derivatives Market and a clearinghouse, The Securities Clearing Centre Company (Muqassa), both of which are running on Nasdaq’s (Nasdaq: NDAQ) market technology. The first exchange-traded derivatives product is MT30 Index Futures, an index futures contract based on the MSCI Tadawul 30 Index (MT30), which will benefit from central counterparty clearing by Muqassa.This new market offering provides regional and international investors the necessary hedging tools to manage risk, and to expand exposure opportunities to one of the largest and most liquid markets in the world, the Saudi market. As the market infrastructure develops, Tadawul plans to roll out more derivatives...

Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 were on inclisiran) 1 New post-hoc analysis demonstrates 99% of patients treated with inclisiran showed placebo-adjusted reduction in low-density lipoprotein cholesterol (LDL-C) of ≥30% with a mean reduction of 54.1% from baseline (observed values)2 88% of inclisiran-treated patients achieved LDL-C placebo-adjusted reduction of at least 50% at any time point during the study (observed values)2 Inclisiran is currently under review by the FDA and the EMA for the treatment of primary hyperlipidemia (including Heterozygous Familial Hypercholesterolemia) in adults who have elevated LDL-C while being on a maximally tolerated dose of statin therapyBasel,...